AbbVie (NYSE: ABBV) announced today that Health Canada has approved QULIPTA (atogepant) for the prevention of migraine in adults who have at least four migraine days per month.1 QULIPTA is the first and only oral, small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) approved to prevent both episodic and chronic migraine.
Shares of Teva Pharmaceutical Industries have done something unusual this year: They’ve gone up. The company’s American depositary receipt, which spent much of the past decade falling in value or stagnating at rock-bottom levels, has shot up nearly 35% this year. On Wednesday morning, executives will present the Teva’s first-quarter results, and face questions from Wall Street about whether the company can sustain this upswing.
In this article, we discuss 15 best S&P 500 dividend stocks to buy now. You can skip our detailed analysis of dividend stocks in the S&P 500 and their past performance, and go directly to read 5 Best S&P 500 Dividend Stocks To Buy Now. It’s been a dynamic first quarter for the stock market. […]